IP Library Granted Patent US 9,492,550
Granted Patent B2
US 9,492,550 · App. 14/186,147 · Granted Nov 15, 2016

Pharmaceutical compositions with enhanced performance and improved processability

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,492,550
App. No.
14/186,147
Granted
Nov 15, 2016
Kind
B2
Abstract

The presently disclosed and claimed inventive concept(s) relates to a polymer for enhancing drug performance and improving processability. Specifically, the polymer comprises hydroxypropyl methyl cellulose acetate succinate (HPMC-AS). On the HPMC-AS, the percentage of total succinoyl degree of substitution is less than 12% at C6-OH position and greater than 53% at C3-OH, and the percentage of total acetyl degree of substitution is greater than 32% at C6-OH position.

Claims (9)

1. A polymer for enhancing drug performance and improving processability, wherein the polymer is hydroxypropyl methyl cellulose acetate succinate having:

a percentage of a total degree of substitution (DS) of succinoyl less than or equal to 6% at a C6-OH position (%C 6 DS Suc ≦6%) and from 58% to 84% at a C3-OH position (58% <%C 3 DS Suc <84%), and

a percentage of a total DS of acetyl from 33% to 51% at a C6-OH position (33%<%C 6 DS Ac <51%) and from 16% to 20% at the C3-OH position (16%<%C 3 DS Ac <20%).

2. A composition comprising a drug and a polymer, wherein the polymer is hydroxypropyl methyl cellulose acetate succinate having:

a percentage of a total degree of substitution (DS) of succinoyl less than or equal to 6% at a C6-OH position (%C 6 DS Suc ≦6%) and from 58% to 84% at a C3-OH position (58%<%C 3 DS Suc <84%), and

a percentage of a total DS of acetyl from 33% to 51% at a C6-OH position (33%<%C 6 DS Ac <51%) and from 16% to 20% at the C3-OH position (16% <%C 3 DS Ac <20%).

3. The composition of claim 2 , wherein the drug is a low-solubility drug having a solubility equal to or less than about 0.5 mg/mL in an aqueous solution at a pH from 1 to 8.

4. The composition of claim 3 , wherein the composition comprises a solid amorphous dispersion comprising the low-solubility drug and the polymer.

5. The composition of claim 3 , wherein the composition comprises a physical mixture of the low-solubility drug and the polymer.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 10, 2020
From: THE BANK OF NOVA SCOTIA
To: AVOCA LLC; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES LLC
Reel/Frame 051557/0504 →
SECURITY AGREEMENT Recorded Jul 3, 2017
From: AVOCA, INC.; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES, INC.
To: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT
Reel/Frame 043084/0753 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2016
From: HERCULES INCORPORATED
To: HERCULES LLC
Reel/Frame 040246/0617 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2014
From: BRUGEL, TODD A; NGUYEN, TUYEN T; SAHOO, SANGRAMA; TEWARI, DIVYA; ZONG, YUDA
To: HERCULES INCORPORATED
Reel/Frame 032312/0311 →